Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Replacement for Bortezomib or Carfilzomib in Relapsed/Refractory Multiple Myeloma
NCT02206425Phase 2Completed
- Sponsor
- ONCOtherapeutics
- Start
- Sep 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in multiple myeloma (MM) (10 arms), sponsored by ONCOtherapeutics. Primary endpoints: Maximum Tolerated Dose, Number of subjects with adverse events up to 48 months and 2 more. Started Sep 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02206425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206425.